Quantifying quality attributes of AAV gene therapy vectors by SEC-UV-MALS-dRI

Applications |  | Wyatt Technology | WatersInstrumentation
GPC/SEC
Industries
Pharma & Biopharma
Manufacturer
Agilent Technologies, Waters
Downloadable PDF for viewing
 

Similar PDF

Enhanced SEC-MALS analysis of therapeutic mAbs, biosimilars and AAVs with XBridge Premier columns
Next Steps in AAV Characterization via Light Scattering Measuring AAV Critical Quality Attributes
Heightened Characterization of AAVs by SEC-MALS with XBridge Premier GTx BEH SEC 450 Å 2.5 μm Columns
Advances in Downstream PAT for Biologics, Vaccines and Gene Vectors